tbuckley/cabot-search huggingface dataset:
Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
Authors: F Lévi, M Benavides, C Chevelle, F Le Saunier, F Bailleul, J L Misset, C Regensberg, J M Vannetzel, A Reinberg, G Mathé
Journal: Journal of Clinical Oncology (1990)

The efficacy and toxicity of the new anthracycline, 4'-0-tetrahydropyranyl doxorubicin (THP) (50 mg/m2 intravenous [IV] bolus) in association with cisplatin (100 mg/m2 IV as a 4-hour infusion) was assessed in 31 patients with advanced ovarian carcinoma. Twenty-eight patients were assessable for toxicity among whom 25 were assessable for response (International Federation of Gynecology and Obstetrics [FIGO] stage IIIa, four patients; IIIb, 15 patients; IV, six patients). Nine patients had received prior treatment. Patients were randomized to receive schedule (sch) A (THP at 6 hours, then cisplatin from 16 to 20 hours) or sch B (THP at 18 hours, then cisplatin from 4 to 8 hours). Sch A was hypothesized as less toxic since THP was best tolerated in the late rest span and cisplatin near the middle of the activity span in experimental studies. The rate of clinical complete response (CR) was 52%, that of partial response (PR) was 12%, and the overall clinical response rate (CR plus PR) was 64% (sch A, 73%; sch B, 57%). Median progression-free survival and survival times were, respectively, 10 and 19 months. Of 12 patients in clinical CR evaluated at second-look laparotomy, four had a pathological CR (33%), and three had microscopic residual disease (MD). The overall rate of pathological CR was 16%. Sch A was associated with less neutropenia (P = .10), thrombocytopenia (P less than .01), anemia (P less than .01), and renal toxicity (P less than .05) than sch B. Of four patients withdrawn for toxicity, three were on sch B (one death). Mean dose intensities (DIs) of THP and cisplatin, respectively, decreased by 30% and 47% over the five initial courses. Such decrease was significantly more pronounced for sch B than for sch A in previously untreated patients (P from 2-way analysis of variance [ANOVA] less than .01). THP-cisplatin is active against advanced ovarian cancer, and its toxicities can be significantly decreased by dosing THP in the early morning and cisplatin in the late afternoon as compared with THP in the evening and cisplatin the next morning.
Comparison of medical resource use and associated cost before and after docetaxel treatment among prostate cancer patients.
Authors: M. Mehra, Y. Wu, R. Dhawan
Journal: Journal of Clinical Oncology (2011)

e15068 Background: Docetaxel is standard of care among metastatic castrate resistant prostate cancer patients. We analyzed patterns of medical resource utilization (RU) and associated cost among these patients before and after exposure to docetaxel using a US patient claims database. Methods: Patients (n=3642) with a diagnosis of prostate cancer (ICD 9 code: 185.X) and a claim for docetaxel (2003–2009) were identified from PharMetrics database, a nationally representative, non-payer-owned integrated commercial US claims database. All patients had ≥ 12 months of enrollment prior to docetaxel and were followed from first docetaxel claim until lost to follow-up or Oct 31, 2009 (censored). RU was defined as all-cause hospitalization, ER, physician, and ambulatory visits. Allowable payment for treatments and RU were tracked. Results: Mean age of patients was 69.6 years (SD 10.2); mean number of docetaxel prescriptions was 10 (SD 11.7). The table shows rates of RU for the 12 months before, and over the follow-up period after docetaxel initiation. Hospitalizations, ER, physician, and ambulatory visits were significantly higher in the follow-up period. Average post-docetaxel length of hospital stay was also longer (7.8 vs 6.0 days). About 2/3 of pts. were on hormonal therapies before docetaxel. After docetaxel, use of prednisone, other chemotherapies, analgesics, and bisphosphanates increased. Average cost PPPM (including treatments and RU) before docetaxel was $2,593 (median $1,620), compared to $5,847 (median $4,345) after docetaxel. Conclusions: RU and cost increased significantly post docetaxel in these patients suggesting need for new treatment options that can effectively manage and improve patient outcomes. Pre-docetaxel Post-docetaxel # of pts. # of events Count PPPMa (SD) # of pts. # of events Count PPPMa (SD) P valueb Hospitalizations 1,203 1,895 0.05 (0.10) 2,195 4,816 0.12 (0.19) < 0.0001 Average length of stay (days) 6.0 (SD 5.1) 7.8 (SD 6.9) < 0.0001 ER visits 1,383 2,793 0.07 (0.14) 2,272 6,351 0.15 (0.23) < 0.0001 Physician visits 3,458 82,073 2.11 (1.47) 3,614 164,837 3.35 (2.17) < 0.0001 Ambulatory visits 3,490 92,627 2.38 (1.58) 3,635 193,664 3.72 (2.14) < 0.0001 a Per patient per month. b Paired t test.
Management of Breast Cancer During Pregnancy Using a Standardized Protocol
Authors: David L. Berry, Richard L. Theriault, Frankie A. Holmes, Valerie M. Parisi, Daniel J. Booser, S. Eva Singletary, Aman U. Buzdar, Gabriel N. Hortobagyi
Journal: Journal of Clinical Oncology (1999)

PURPOSE: No standardized therapeutic interventions have been reported for patients diagnosed with breast cancer during pregnancy. Of the potential interventions, none have been prospectively evaluated for treatment efficacy in the mother or safety for the fetus. We present our experience with the use of combination chemotherapy for breast cancer during pregnancy. PATIENTS AND METHODS: During the past 8 years, 24 pregnant patients with primary or recurrent cancer of the breast were managed by outpatient chemotherapy, surgery, or surgery plus radiation therapy, as clinically indicated. The chemotherapy included fluorouracil (1,000 mg/m 2 ), doxorubicin (50 mg/m 2 ), and cyclophosphamide (500 mg/m 2 ), administered every 3 to 4 weeks after the first trimester of pregnancy. Care was provided by medical oncologists, breast surgeons, and perinatal obstetricians. RESULTS: Modified radical mastectomy was performed in 18 of the 22 patients, and two patients were treated with segmental mastectomy with postpartum radiation therapy. This group included patients in all trimesters of pregnancy. The patients received a median of four cycles of combination chemotherapy during pregnancy. No antepartum complications temporally attributable to systemic therapy were noted. The mean gestational age at delivery was 38 weeks. Apgar scores, birthweights, and immediate postpartum health were reported to be normal for all of the children. CONCLUSION: Breast cancer can be treated with chemotherapy during the second and third trimesters of pregnancy with minimal complications of labor and delivery.
Psychiatric Evaluation of Those Returning from Combat
Authors: Lieutenant Colonel John M. Murray
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience.
Authors: M Hudson, M R Jaffe, N Jaffe, A Ayala, A K Raymond, H Carrasco, S Wallace, J Murray, R Robertson
Journal: Journal of Clinical Oncology (1990)

Ninety-eight pediatric patients were treated with three separate protocols (Treatment and investigation of Osteosarcoma [TIOS] I, II, and III) and 47 developed recurrent disease (metastases and/or local recurrence). Actuarial overall disease-free survival (hereafter designated survival) was 43%. Over 90% of the patients were treated initially with preoperative intraarterial cisplatin (CDP). Postoperative chemotherapeutic regimens comprised high-dose methotrexate with leucovorin rescue (MTX-CF), Adriamycin [( ADR] doxorubicin; Adria Laboratories, Columbus, OH), and cyclophosphamide. Primary definitive treatment comprised amputation or limb salvage (TIOS I and TIOS III). Patients treated with preoperative CDP and surgery (TIOS I and III) had a 62% survival. Patients in TIOS II refused surgical extirpation; they were treated exclusively with chemotherapy and had a 23% survival. Survival in patients treated with amputation was 55% and limb salvage 58%. Prognostic factors considered significant in relation to development of pulmonary metastases comprised tumor burden (P = .04) and the percentage of tumor necrosis induced by preoperative chemotherapy (P = .01). Histopathologic subtype was marginally significant: chondroblastic was more favorable as opposed to osteoblastic (P = .05). These findings are compared with results and prognostic factors published in the literature.
Abstract P2-13-20: Randomized clinical trial comparing 2-octylcyanoacrylate versus intradermic suture with nylon: Similar cosmetic results with different safety profile
Authors: Ruffo Freitas-Junior, Thiago S Becker, Rosemar MS Rahal, Regis R Paulinelli
Journal: Cancer Research (2015)

Abstract Introduction: There are multiple options available for closing surgical incisions. This study compared the cosmetic results between the use of 2-octylcyanoacrylate and nylon sutures in elective breast surgery. Objectives: To compare the efficacy and cosmetic outcome between the adhesive and conventional suturing with nylon on the cutaneous synthesis mammary surgeries. Methods: we performed a prospective, randomized, controlled trial with 79 patients, 37 in group 2-octylcyanoacrilate and 42 in the group with nylon suture. We evaluated the surgical aspect of the scar in 40 and 180 days, the occurrence of complications (such as dehiscence, hematoma, infection and allergic reactions), the size of the wound and breast lesions, surgical time and skin closure time, hemoglobin and preoperative WBC, age, height and weight of patients. Statistical analysis was performed by t test and chi-square. Results and discussion: the study was stopped before the end of the recruitment of patients for the presence of a greater number of dehiscence in the adhesive group (OR: 11.42, 95% CI 1.36 - 96.02, p=0.007). There were no significant differences between the groups regarding other complications, not in relation to surgical time and the aesthetic appearance of scars after 40 and 180 days. The average size of the wound was greater in the adhesive group than in the suture, being respectively 32.97 (+ 10.54) mm and 27.64 (+ 9.56) mm, no correlation of size with the largest number of dehiscence. Conclusion: The results showed that the cosmetic scar appearance of 2-octylcyanoacrilate is equivalent to those obtained with the intradermal nylon suture, but the risk of dehiscence is higher. Citation Format: Ruffo Freitas-Junior, Thiago S Becker, Rosemar MS Rahal, Regis R Paulinelli. Randomized clinical trial comparing 2-octylcyanoacrylate versus intradermic suture with nylon: Similar cosmetic results with different safety profile [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-13-20.
Radiotherapeutic Management of Non–Small Cell Lung Cancer in the Minimal Resource Setting
Authors: Danielle Rodin, Surbhi Grover, Melody J. Xu, Timothy P. Hanna, Robert Olson, L. John Schreiner, Anusheel Munshi, Francoise Mornex, David Palma, Laurie E. Gaspar
Journal: Journal of Thoracic Oncology (2016)
Association of a novel polymorphism G-133C of thymidylate synthase (TYMS) gene with 5-FU-related severe diarrhea in Japanese patients with colorectal cancer
Authors: Y. Matsumura, M. Muto, T. Doi, A. Ohtsu, T. Hamaguchi, Y. Shimada, Y. Yamada, K. Shirao, N. Kaniwa, J. Sawada
Journal: Journal of Clinical Oncology (2007)

14108 Background: 5-FU remains a key drug for the treatment of several cancers, including cancers of the colorectum, stomach, and breast. Increasing evidence suggests that genetic polymorphism results in increased toxicity. This prospective study intended to elucidate the relations between 5-FU-related toxicity and polymorphisms of several genes. Methods: Blood for genotyping was obtained before treatment. Blood samples were drawn at 2-week intervals for 8 weeks to assess hematologic toxicity. Adverse events were assessed according to NCI CTC, v2.0. The genes encoding TYMS and thymidine phosphorylase (ECGF1) were analyzed with leukocyte DNA obtained from patients with colorectal cancer who received 5-FU (500 or 600 mg/m 2 ) and leucovorin (LV) (250 mg/m 2 ) weekly for 6 weeks every 8 weeks. Results: Seventy-eight patients with colorectal cancer were enrolled and genotyped. Toxicity was evaluated in all patients. No genetic polymorphisms detected were significantly associated with 5-FU-related hematological toxicity. Only G- 133C located in the 5’-UTR region of the TYMS gene was significantly associated with 5-FU-related grade 3 diarrhea. Conclusions: The TYMS G-133C SNP may be a critical determinant of severe diarrhea in patients treated with 5-FU/LV. [Table: see text] No significant financial relationships to disclose.
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection
Authors: David J. DiLillo, Peter Palese, Patrick C. Wilson, Jeffrey V. Ravetch
Journal: Journal of Clinical Investigation (2016)

In vivo protection by antimicrobial neutralizing Abs can require the contribution of effector functions mediated by Fc-Fcγ receptor (Fc-FcγR) interactions for optimal efficacy. In influenza, broadly neutralizing anti-hemagglutinin (anti-HA) stalk mAbs require Fc-FcγR interactions to mediate in vivo protection, but strain-specific anti-HA head mAbs do not. Whether this rule applies only to anti-stalk Abs or is applicable to any broadly neutralizing Ab (bNAb) against influenza is unknown. Here, we characterized the contribution of Fc-FcγR interactions during in vivo protection for a panel of 13 anti-HA mAbs, including bNAbs and non-neutralizing Abs, against both the stalk and head domains. All classes of broadly binding anti-HA mAbs required Fc-FcγR interactions to provide protection in vivo, including those mAbs that bind the HA head and those that do not neutralize virus in vitro. Further, a broadly neutralizing anti-neuraminidase (anti-NA) mAb also required FcγRs to provide protection in vivo, but a strain-specific anti-NA mAb did not. Thus, these findings suggest that the breadth of reactivity of anti-influenza Abs, regardless of their epitope, necessitates interactions with FcγRs on effector cell populations to mediate in vivo protection. These findings will guide the design of antiviral Ab therapeutics and inform vaccine design to elicit Abs with optimal binding properties and effector functions.
Nasal Spray to Stop Overdose
Authors: Rebecca Voelker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation
Authors: Yafei Hou, Gary Kohanbash, Kaori Okada, Shruti Shrivastav, Matthew Smith-Cohn, Theodore Nicolaides, Sabine Mueller, Angel Carcaboso, Ian Pollack, Hideho Okada
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Malignant gliomas, such as glioblastoma (GBM) and diffuse intrinsic pontine gliomas (DIPG), are lethal brain tumors in both adults and children. Indeed, brain tumors are the leading cause of cancer-related mortality and morbidity in children. Children with DIPG have one-year
Intraprocedural TAVR Annulus Sizing Using 3D TEE and the “Turnaround Rule”
Authors: Brandon M. Wiley, Jason C. Kovacic, Sandeep Basnet, Amaki Makoto, Farooq A. Chaudhry, Annapoorna S. Kini, Samin K. Sharma, Partho P. Sengupta
Journal: JACC. Cardiovascular imaging (2015)
Assessing mechanical properties of benign and malignant prostate tissue.
Authors: T. L. Krupski, C. Gundersen, W. C. Carson, C. Moskaluk, J. Harper, G. J. Gerling
Journal: Journal of Clinical Oncology (2010)

e15109 Background: We aimed to characterize material stiffness, specifically elastic recoil, of prostate tissue in normal and disease states. Conceivably, differences in stiffness may lead to the detection of prostate carcinoma by digital rectal exam or possibly prostate biopsy. We hypothesize that malignant prostate tissue is stiffer than benign prostate tissue. Methods: We evaluated 15 ex vivo prostatectomy specimens using a custom-built and portable spherical indentation device that builds force-displacement curves to calculate elastic modulus. At the time of surgical extirpation, the team carried prostatectomy specimens to the pathology suite. After the prostate was sectioned from apex to base, elasticity measurements on the tissue samples for histopathological analysis were taken in each quadrant of the 2mm cross-sections in such a way as to not violate the standard TNM pathologic evaluation. Data were excluded if corresponding tissue histology was high-grade prostatic intraepithelial neoplasia or <10% adenocarcinoma. We performed a chart extraction to compare cross-sectional pathology and tissue properties with digital rectal exam findings and clinical and pathological staging. All portions of the study were IRB approved. Results: The 15 gross prostates yielded 40 cross-sections. From the cross-sections, there were 160 elastic modulus measurements with corresponding histology. The median elastic modulus for adenocarcinoma, normal tissue, prostatitis, benign prostatic hypertrophy (BPH), and prostatitis respectively were 45,993 (N1=34), 22,741 (N2=56), 20,718 (N3=9), and 16,653 (N4=24) pascals. By further comparing elastic moduli of malignant and benign tissue between the quadrants within a single cross-section, we found malignant tissue to be an average of 56.9% firmer than benign tissue. Conclusions: Mechanical testing results revealed that malignant tissue is stiffer than normal prostate tissue, while tissue with BPH or prostatitis are less stiff than normal tissue. These promising results suggest tissue elasticity may be an accurate indicator of prostate carcinoma. No significant financial relationships to disclose.
Immunohistochemical Studies on the Antigenic Relationship of Some Muscle Tumors to Normal Skeletal Muscle Cells&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: R. Hiramoto, J. Cairns, D. Pressman
Journal: JNCI Journal of the National Cancer Institute (1961)

Normal skeletal muscle cells, when grown in tissue culture, appeared to shift from the production of myosin to a production of connective-tissue components. That an actual shift of production was taking place and that the observed change in cell population was not entirely due to an outgrowth of one particular type of cell with a decrease growth of another were shown clearly by a paired fluorescent-label technique. Individual cells could be found that contained both connective-tissue components and myosin. This change is of significance in connection with rhabdomyosarcomas in which a similar change would explain the previous observations that some human rhabdomyosarcomas contain myosin while others do not. The latter seem to contain connective-tissue components that are not observed in the rhabdomyosarcomas containing myosin. It would appear that the rhabdomyosarcomas not containing myosin were either not derived from muscle or had lost the ability to produce enough myosin to be seen and were producing enough connective-tissue components to be readily demonstrated.
To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater.
Authors: H R Franklin, H Schraffordt Koops, J Oldhoff, B M Czarnetzki, E Macher, B B Kroon, K Welvaart, J W van der Velden, E van Dijk, E P van der Esch
Journal: Journal of Clinical Oncology (1988)

The use of isolated regional perfusion in an adjuvant setting for stage I melanoma of the extremity continues to be controversial. The present retrospective study evaluates the past 20 years' experience by comparing 227 perfused patients from Groningen with 238 matched controls from five hospitals in The Netherlands and Westphalia (a region of West Germany bordering the Netherlands). All patients underwent wide local excision for a primary extremity melanoma of 1.5 mm or greater in thickness. A proportional hazards regression analysis for recurrence of disease and survival identified the significant prognostic factors, of which tumor thickness was the most important. Corrected for these factors, it was not possible to demonstrate a statistically significant effect for perfusion in terms of time to limb recurrence (P = .61), time to regional lymph node metastasis (P = .11), time to distant metastasis (P = .73), disease-free interval (P = .42), and survival (P = .90). No statistically significant differences were seen for adjuvant perfusion in any of the subgroups.